Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
COZAAR vs INJECTAPAP
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Losartan is a selective angiotensin II receptor type 1 (AT1) antagonist. It blocks the binding of angiotensin II to AT1 receptors in vascular smooth muscle and adrenal gland, leading to vasodilation, reduced aldosterone secretion, and decreased blood pressure. It also reduces proteinuria and slows progression of renal disease by decreasing intraglomerular pressure.
Acetaminophen is a centrally acting analgesic and antipyretic; its exact mechanism is not fully understood but involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system and modulation of descending serotonergic pathways. It does not have significant anti-inflammatory activity.
Hypertension,Nephropathy in patients with type 2 diabetes and hypertension,Hypertension with left ventricular hypertrophy (to reduce risk of stroke)
Management of mild to moderate pain,Reduction of fever
50 mg orally once daily; may increase to 100 mg once daily based on blood pressure response.
1 g intravenous every 6 hours or 650 mg intravenous every 4 hours; maximum 4 g per day.
Plasma half-life of losartan: approximately 2 hours; active metabolite E-3174: 6–9 hours. Clinical context: once-daily dosing due to prolonged receptor blockade by metabolite
2-3 hours in adults; prolonged to 4-6 hours in neonates and patients with hepatic impairment.
Losartan is extensively metabolized in the liver via CYP2C9 and CYP3A4 to its active metabolite, E-3174, which is more potent than the parent drug. E-3174 is further metabolized to inactive metabolites. Both losartan and E-3174 are excreted in urine and feces.
Primarily metabolized in the liver via conjugation (glucuronidation and sulfation) at therapeutic doses; a minor pathway via cytochrome P450 (CYP2E1, CYP1A2, and CYP3A4) produces a toxic metabolite (NAPQI) which is normally detoxified by glutathione.
Renal (35% as unchanged drug and 18% as active metabolite), biliary/fecal (approximately 60% of radiolabeled dose recovered in feces)
Renal: 2-5% unchanged; hepatic metabolism to glucuronide and sulfate conjugates, then renal excretion of metabolites. Biliary/fecal: minimal (<5%).
≥99% (primarily albumin); losartan ≥98.7%, active metabolite ≥99.8%
10-25% bound to albumin at therapeutic concentrations.
Losartan: 34 L (0.47 L/kg for 70 kg adult); active metabolite: 12 L. Indicates limited extravascular distribution
0.8-1.0 L/kg; suggests distribution into total body water.
Oral: about 33% (losartan); active metabolite bioavailability not directly reported but formed via first-pass metabolism
IV: 100%; oral: 60-90% (first-pass metabolism); rectal: 30-50%.
No dose adjustment required for GFR ≥30 m L/min; for GFR <30 m L/min, initial dose is 25 mg orally once daily.
For GFR 30-60 m L/min: no adjustment; for GFR <30 m L/min: extend interval to every 8 hours; maximum 3 g per day.
For Child-Pugh Class A or B: initial dose is 25 mg orally once daily; no data for Class C.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%, maximum 2 g per day; Child-Pugh C: contraindicated.
For children ≥6 years: initial dose 0.7 mg/kg (up to 50 mg) orally once daily; maximum 1.4 mg/kg (up to 100 mg) once daily.
For weight ≥50 kg: 1 g every 6 hours; for weight 10-50 kg: 15 mg/kg every 6 hours; for weight <10 kg: 7.5 mg/kg every 6 hours; all intravenous.
Consider lower initial dose of 25 mg orally once daily due to potential for volume depletion or decreased renal function.
No specific dose adjustment required; consider decreased hepatic function and concomitant medications; maximum 3 g per day for patients with risk factors for hepatotoxicity.
None
Acetaminophen has been associated with cases of acute liver failure, hepatotoxicity is primarily due to overdose. Risk is increased in patients with underlying liver disease, chronic alcohol use, and those taking multiple acetaminophen-containing products.
Fetal toxicity (discontinue when pregnancy is detected); hypotension in volume-depleted patients; renal impairment (monitor serum creatinine and potassium); hyperkalemia; angioedema; dual blockade of renin-angiotensin system (increased risk of hypotension, hyperkalemia, renal dysfunction); hepatotoxicity; monitor for azotemia in renovascular hypertension.
Risk of hepatotoxicity, especially with doses exceeding 4 g/day or in patients with liver impairment,Severe skin reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, and acute generalized exanthematous pustulosis,Hypersensitivity reactions,Use caution in patients with G6PD deficiency,Avoid use with other acetaminophen-containing products
Hypersensitivity to losartan or any component; pregnancy (especially second and third trimesters); concomitant use with aliskiren in patients with diabetes mellitus or renal impairment (e GFR <60 m L/min/1.73m²); history of angioedema related to previous ARB therapy.
Hypersensitivity to acetaminophen or any component of the formulation
No significant food interactions. However, avoid high-potassium foods (such as bananas, oranges, leafy greens, tomatoes, and avocados) in large amounts if taken with potassium supplements or if renal function is impaired. Limit salt intake as advised for hypertension management. Grapefruit juice does not interact significantly with losartan.
No significant food interactions. However, concurrent ingestion of alcohol may increase risk of hepatotoxicity; avoid alcohol while on therapy.
Contraindicated in pregnancy. First trimester: Associated with congenital malformations, including renal dysplasia and oligohydramnios. Second and third trimesters: Fetal toxicity (oligohydramnios, pulmonary hypoplasia, skull ossification defects, neonatal anuria, hypotension, and death).
FDA Category C. Acetaminophen crosses the placenta. No evidence of teratogenicity in humans with standard doses. First trimester: limited data suggest no increased risk of major malformations. Second and third trimesters: chronic high-dose use may be associated with increased risk of childhood asthma and attention-deficit/hyperactivity disorder (ADHD). Overdose poses risk of maternal and fetal hepatotoxicity.
Not recommended. No data on M/P ratio; excreted in rat milk; potential for adverse effects in nursing infant due to renin-angiotensin system blockade.
Acetaminophen is excreted into breast milk in low concentrations (M/P ratio approximately 0.91-1.42). Reported infant dose is less than 2% of maternal weight-adjusted dose. Considered compatible with breastfeeding. Use lowest effective dose for shortest duration.
Contraindicated; no dose adjustments recommended as use should be avoided; alternative antihypertensives preferred.
No dose adjustment required for standard therapeutic use. Increased clearance in pregnancy may require shorter dosing intervals for pain control; consider maximum daily dose of 3 g/day instead of 4 g/day. Avoid prolonged use >48 hours without medical supervision.
Cozaar (losartan) is an angiotensin II receptor blocker (ARB). Monitor renal function and electrolytes, especially potassium, within 2-4 weeks of initiation and periodically thereafter. May cause a reversible rise in serum creatinine, especially in renal artery stenosis. Has a uricosuric effect, modestly lowering uric acid levels. Avoid use in pregnancy (category D). Dose adjustment recommended for hepatic impairment. Can be used as an alternative in patients who develop ACE-inhibitor-induced cough.
Acetaminophen injection is indicated for treatment of acute pain and fever. Use with caution in hepatic impairment. Avoid in patients with severe active liver disease. Monitor liver function tests with prolonged use. Do not exceed maximum daily dose (4 g/day in adults). Use the smallest effective dose for the shortest duration.
Take once daily with or without food; consistency in timing is key.,Avoid potassium supplements or salt substitutes containing potassium unless directed by your doctor.,May cause dizziness, especially at start; avoid driving until you know how it affects you.,Do not use if pregnant, planning pregnancy, or breastfeeding; discuss contraception with your doctor.,Report symptoms like fainting, rapid heartbeat, or leg swelling to your doctor.,Stay well-hydrated, especially if you experience diarrhea or vomiting, as dehydration can worsen side effects.,Do not stop this medication abruptly; consult your physician before discontinuing.
Do not take more than the recommended dose. Overdose can cause severe liver damage.,Inform your healthcare provider if you have liver disease or drink alcohol regularly.,Check other medications for acetaminophen to avoid double dosing.,Seek immediate medical attention if you experience signs of liver injury (e.g., yellowing skin/eyes, dark urine, upper stomach pain).,This medication is administered by intravenous infusion; do not attempt self-administration.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about COZAAR vs INJECTAPAP, answered by our medical review team.
COZAAR is a Angiotensin Receptor Blocker that works by Losartan is a selective angiotensin II receptor type 1 (AT1) antagonist. It blocks the binding of angiotensin II to AT1 receptors in vascular smooth muscle and adrenal gland, leading to vasodilation, reduced aldosterone secretion, and decreased blood pressure. It also reduces proteinuria and slows progression of renal disease by decreasing intraglomerular pressure.. INJECTAPAP is a Non-Opioid Analgesic that works by Acetaminophen is a centrally acting analgesic and antipyretic; its exact mechanism is not fully understood but involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system and modulation of descending serotonergic pathways. It does not have significant anti-inflammatory activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between COZAAR and INJECTAPAP depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of COZAAR is: 50 mg orally once daily; may increase to 100 mg once daily based on blood pressure response.. The standard adult dose of INJECTAPAP is: 1 g intravenous every 6 hours or 650 mg intravenous every 4 hours; maximum 4 g per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between COZAAR and INJECTAPAP in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. COZAAR is classified as Category C. Contraindicated in pregnancy. First trimester: Associated with congenital malformations, including renal dysplasia and oligohydramnios. Second and third trimesters: Fetal toxicity . INJECTAPAP is classified as Category C. FDA Category C. Acetaminophen crosses the placenta. No evidence of teratogenicity in humans with standard doses. First trimester: limited data suggest no increased risk of major ma. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.